{"organizations": [], "uuid": "bfadb26a71056d1eabcc60d57b3b08a4c8a27174", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-redhill-biopharma-reports-enrollme/brief-redhill-biopharma-reports-enrollment-of-300th-patient-in-confirmatory-phase-iii-study-with-talicia-idUSFWN1SB0NG", "country": "US", "domain_rank": 408, "title": "BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-04T14:12:00.000+03:00", "replies_count": 0, "uuid": "bfadb26a71056d1eabcc60d57b3b08a4c8a27174"}, "author": "", "url": "https://www.reuters.com/article/brief-redhill-biopharma-reports-enrollme/brief-redhill-biopharma-reports-enrollment-of-300th-patient-in-confirmatory-phase-iii-study-with-talicia-idUSFWN1SB0NG", "ord_in_thread": 0, "title": "BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia", "locations": [], "entities": {"persons": [{"name": "talicia", "sentiment": "negative"}, {"name": "h. pylori", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "talicia  redhill biopharma", "sentiment": "neutral"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "redhill biopharma ltd", "sentiment": "none"}, {"name": "redhill biopharma ltd", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 4, 2018 / 11:13 AM / Updated 9 minutes ago BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia Reuters Staff 1 Min Read\nMay 4 (Reuters) - Redhill Biopharma Ltd:\n* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIAÂ® FOR H. PYLORI INFECTION\n* REDHILL BIOPHARMA LTD - EXPECTS TO COMPLETE ENROLLMENT IN Q3/2018 AND ANNOUNCE TOP-LINE RESULTS IN Q4/2018\n* REDHILL BIOPHARMA LTD - STUDY IS EXPECTED TO COMPLETE PACKAGE REQUIRED FOR FILING A U.S. NDA FOR TALICIA IN EARLY 2019\n* REDHILL BIOPHARMA LTD - IF ACCEPTED, TALICIA NDA WILL BENEFIT FROM PRIORITY REVIEW OF 6 MONTHS WITH POTENTIAL FDA APPROVAL IN H2/2019\n* REDHILL BIOPHARMA LTD - REMAINS ON TRACK TO POTENTIALLY COMPLETE ENROLLMENT OF ERADICATE HP2 STUDY IN Q3 OF 2018\n* REDHILL BIOPHARMA LTD - EXPECTS TO ANNOUNCE TOP-LINE RESULTS OF ERADICATE HP2 STUDY IN Q4 OF 2018 Source text for Eikon: ", "external_links": [], "published": "2018-05-04T14:12:00.000+03:00", "crawled": "2018-05-04T14:24:29.012+03:00", "highlightTitle": ""}